Seventh Version Standard Therapy Published and National Award Winner Lianhua Qingwen Contributes to Prevention and Control of Epidemic Outbreak
On March 3, the Standard Therapy for Novel Coronavirus Pneumonia (Version VII, Tentative) was published by the National Health Commission and the National Administration of Traditional Chinese Medicine together. Ever since the outbreak of the epidemic disease, there have been 5 versions of the national standard therapy that recommended the use of TCM patent drugs and all of them recommended the use of Lianhua Qingwen Capsules and Granules to be used for the treatment during the medical observation period.
During the recent days, Professor Zhang Junhua of the Evidence Based Medicine Center of Tianjin University of Traditional Chinese Medicine published a paper named the Analysis of the Rules on Recipes and Syndromes for the Prevention and Treatment of Novel Coronavirus Pneumonia by Traditional Chinese Medicine. In the 23 proposed therapies for Novel Coronavirus Pneumonia published all around the country, such as Guangdong, Hebei, Zhejiang and Shandong, listed in the paper, Lianhua Qingwen Capsules (Granules) is most frequently cited. It is recommended in altogether 18 of the therapies and it is the TCM patent drug that is most frequently recommended for the treatment of Novel Coronavirus Pneumonia.
The first reason why Lianhua Qingwen is frequently recommended is that the scientific research achievements of Lianhua Qingwen Capsules have won the Annual Second-class Prize of the National Science and Technology Progress Award in 2011, which is an advantage that no other similar products have. Ever since the launching of Lianhua Qingwen in 2004 to its application in the treatment of Novel Coronavirus Pneumonia this year, it has been recognized as the recommended product from the national level for more than 20 times and it has been widely used for the prevention and treatment of such virus infectious major public health emergency events as influenza, avian influenza and Novel Coronavirus Pneumonia in China.
Lianhua Qingwen has Multi-target Actions in Prevention and Treatment of Novel Coronavirus Pneumonia
The paper The Study and Preliminary Demonstration of the Network Pharmacology of Lianhua Qingwen for the Treatment of Novel Coronavirus Pneumonia (2019-nCoV) recently published in the Journal of Traditional Chinese Medicinal Materials has proved that Lianhua Qingwen has multi-target actions for the treatment of Novel Coronavirus Pneumonia.
The Lianhua Qingwen uses the collateral disease theory of TCM in addressing the rules and the treatment of external-contraction warm diseases and the spreading of epidemic diseases. A kind of therapy with "active intervention" is proposed to treat the defensive energy, relieve both the interior and the exterior syndromes, use the drug products against the early syndromes to block the development of the disease, stress on overall adjustment and allow the therapy to be multi-target. So the therapy of "heat-clearing, detoxifying, lung ventilating and heat dispelling" is developed. The recipe absorbs the essence of all the recipes for the treatment of febrile diseases and epidemic diseases by numerous famous doctors of all ages. The hemp apricot decoction recorded in the Treatise on Febrile Diseases and the Forsythia Powder recorded in the Treatise on Differentiation and Treatment of Epidemic Febrile Diseases are combined together, and the experience of the use of rheum officinale for the treatment of epidemic diseases proposed in the Treatise on Pestilence by Wu Youke of Ming Dynasty is also referenced to expel the evil and block the development of the disease. Agastache rugosa is used to remove dampness by aromatics, avoid dirty and eliminate turbid pathogen. Rhodiola rosea is used for compatibility for clearing the lungs, dispersing stasis, and adjusting the immunity, which shows the characteristic of this recipe in active intervention.
In the Epidemic Disease Prevention and Control Press Conference held on February 18 by the government of Guangdong province, Professor Yang Zifeng of the team of Academician Zhong Nanshan in the National Key Laboratory of Respiratory Diseases of Guangzhou Medical University says that "It has been shown in the in vitro study that Lianhua Qingwen Capsules (Granules) has significant effects in inhibiting the cytopathic effects of the novel coronavirus cells. We all know that the novel coronavirus we encounter this time is not just a virus. It can also cause a series of over expressions of inflammation. So we also observed the inhibition effects of Lianhua Qingwen Capsules (Granules) on both the common coronavirus (HCoV-229E) and the novel coronavirus (COVID-19) infected cells as well as the over expression of such inflammation factors as the induced TNF-α, IL-6, CCL2/MCP-1 and CXCL-10/IP-10. This is suitable for the clinical inflammation factors." This exactly proves that Lianhua Qingwen has multi-target actions of the inhibition of the novel coronavirus and anti-inflammation.
Professor Yang Zifeng also mentioned that "The study on the use of Lianhua Qingwen for the treatment of the Novel Coronavirus Pneumonia has been completed in 42 definitely diagnosed cases. The study results show that the use of Lianhua Qingwen Granules together with the routine therapy can significantly alleviate such clinical symptoms as fever, coughing and shortness of breath. And the duration of fever is shortened for 1.5 days in average compared with the control group. It also has similar effects on the suspected patients. We can say that this brings hope to the treatment of the Novel Coronavirus Pneumonia, especially for the mild and medium cases. This can really help us solve this emergent situation." The TCM patent drug Lianhua Qingwen is for the syndrome complex of fever, coughing and shortness of breath. Its clinical mechanism of action is also for multiple targets and features at a synergy in anti-inflammation, anti-virus, cough relieving, asthma alleviating, and immunity improvement.
Academician Zhong Nanshan pointed out that such TCM products as Lianhua Qingwen have been commonly used clinically. These TCM products can significantly preventing the intrusion of the viruses into the cells and alleviating the inflammation symptoms. This provides the basis for the use of TCM products in this case.
Lianhua Qingwen Contributes in Preventing and Controlling the Epidemic Emergency
Up to now, Lianhua Qingwen has been used for more than 70 million person times all over the country, more than a million person times in Hubei province alone. Lianhua Qingwen will be used as the basic product in all the mobile cabin hospitals in Wuhan. Lianhua Qingwen Capsules/Granules have been listed as one of the drug products of reserved in many provinces and cities such as Hubei province and Heilongjiang province. They are also listed among the medical emergency products in the list of key assurance materials for the prevention and control of the epidemic emergency by the Ministry of Industry and Information Technology.
When the experts from the World Health Organization visit the mobile cabin hospitals in Wuhan to understand the rescuing of the patients suffering from Novel Coronavirus Pneumonia, Mu Mao of the third medical team supporting Hubei from Guizhou province and the national medical rescue team at the mobile cabin hospital introduced that "All the visiting experts are very interested in whether TCM products are being used in our mobile cabin hospital for the treatment of the Novel Coronavirus Pneumonia through the integrity of TCM and western medicine. And I always tell them that the TCM patent drug Lianhua Qingwen is being used. This is recommended in the standard therapy."
After the wide use of Lianhua Qingwen at the affected areas, satisfactory therapeutic effects have been obtained both for the definitely diagnosed patients and the suspected patients. The reports of the clinical study on the use of Lianhua Qingwen Granules performed by Puren Affiliated Hospital of Wuhan University of Science and Technology, the Ninth Hospital of Wuhan and the CR and WISCO General Hospital have been published in the such journals as the World Traditional Chinese Medicine, the Journal of Traditional Chinese Medicine and the Chinese Journal of Experimental Dosimetry respectively. They prove that Lianhua Qingwen can significantly improve such symptoms as fever, coughing and weakness in definitely diagnosed and suspected cases of Novel Coronavirus Pneumonia and reduce the duration of such symptoms as fever, coughing and weakness. This provides evidences for the clinical therapy of this disease.
Lianhua Qingwen has been recommended for the treatment of all such major virus emergent public health events during the past dozen of years from influenza A, influenza B, avian influenza to Novel Coronavirus Pneumonia. It has been listed as a recommended product in the Guideline on Diagnosis and Treatment of Influenza, the Standard Therapy for Human Beings Infected by Influenza A H1N1, the Standard TCM Therapy for Influenza B Virus Infections, the Standard Therapy for Human Beings Infected by H7N9 Avian Influenza, the Standard Therapy for Influenza (2019), and the Standard Therapy for Novel Coronavirus Pneumonia (Version VII, Tentative). Lianhua Qingwen has been selected as a product of reserve by the local government in many regions for the prevention and treatment of numerous epidemic events.